This paper highlights a circuit-level, exercise-responsive mechanism (cortical transition coding) that could serve as a biomarker or target for non-pharmacological interventions and neuromodulation strategies in PD, providing moderate translational value though it lacks direct molecular therapeutic…

Provides useful synthesis on tau–alpha-synuclein interactions and shared pathogenic pathways that could inform Parkinson's therapeutic target selection or combination strategies, but is primarily conceptual and lacks direct actionable interventions or biomarkers.

The paper presents a novel, testable conceptual framework that could point to new biomarkers and interventions (glycocalyx-targeting therapies, ion modulation, microbiome approaches) but is currently speculative and lacks direct experimental or clinical validation.

Highlights knee OA as a potentially modifiable risk factor that could steer mechanistic work on peripheral inflammation/systemic mediators and motivate prevention or repurposing strategies to lower PD risk.

The study supplies population-level evidence that liver dysfunction modestly correlates with PD risk and highlights liver-related biomarkers that merit mechanistic and translational follow-up, but it is observational and does not provide causal pathways or immediate therapeutic targets for…

The paper provides limited mechanistic or therapeutic leads but is valuable for prioritizing public-health resources and highlighting the urgent need to scale translational and clinical Parkinson's research and care in China due to a large recent rise in PD-related burden.

Moderately high translational value because GLP-1RAs are an already available, mechanism-plausible repurposing class that showed clinically meaningful motor effects in some trials, supporting larger, longer, biomarker-informed trials despite current heterogeneity and tolerability issues.

It highlights a promising cell-based regenerative approach that could inform PD neuroprotection/transplant strategies, but as a broad preclinical review lacking PD-specific mechanistic targets or actionable translational data its immediate value for Parkinson's drug discovery is modest.

Links between GBA1 risk variants and accelerated non-motor progression reinforce lysosomal dysfunction as a therapeutically actionable axis and justify using GBA1 status for trial stratification or targeting, but the results are exploratory and need independent replication before clinical…

By placing SARM1 at the intersection of NAD+ metabolism, PARP1-mediated DNA damage responses, and excitotoxic/MPP+-induced dopaminergic death, the study identifies a druggable, translationally relevant target with strong potential for Parkinson's neuroprotection strategies.

By proposing standardized estimation of aperiodic neural features and linking them to Parkinsonism and DBS modulation, the paper offers moderate translational value for developing reliable biomarkers and adaptive neuromodulation strategies, though it lacks direct molecular or therapeutic targets.

Low direct therapeutic-discovery value, but underscores the importance of patient-reported outcomes and subjective wellbeing when designing exercise interventions, safety guidance, and clinical endpoints in PD research.

While it presents no new experimental data, the paper shifts emphasis toward combination approaches that could enhance translational and repurposing potential by addressing complementary mechanisms and informing future trial design.

Although primarily a mechanistic review rather than a translational study, it highlights inflammation, microglial dysfunction, and gut–brain interactions—pathways highly relevant to Parkinson's disease—that could guide biomarker development and targeted preclinical experiments to assess therapeutic…

MIDN reveals a novel intranuclear proteasomal pathway that could be exploited to modulate disease-relevant transcriptional regulators in Parkinson's disease, offering a potentially actionable therapeutic or biomarker axis although current evidence is review-based and requires experimental…

While primarily a high‑level review with limited direct translational data, it flags BDNF and stress‑axis pathways that overlap with PD‑relevant neuroprotection and metabolic/inflammatory mechanisms, pointing to potential biomarker and repurposing hypotheses for Parkinson's therapeutic research.

The paper highlights exercise as a potentially useful symptomatic, non‑pharmacological strategy and pinpoints methodological gaps (small, heterogeneous trials, lack of PD‑specific fatigue measures) that should guide future mechanistic and sufficiently powered clinical studies, but it offers limited…

By linking ATP13A2 loss-of-function to varying levels of cellular iron overload and rescuability by wild-type protein, the work supports iron-targeted or ATP13A2-restoration therapeutic strategies and offers a more sensitive cellular biomarker approach when MRI is inconclusive for…

A Phase III-ready, non-dopaminergic small molecule targeting a novel GPCR (GPR6) has strong translational relevance and potential to provide new symptomatic or disease-modifying strategies, though the lack of an abstract limits assessment of mechanistic and biomarker data.

Moderately useful for Parkinson's therapeutic discovery because it highlights scalable, non-invasive digital biomarkers and rehabilitative interventions that can aid early detection, patient stratification, and trial endpoints, but it lacks actionable molecular mechanisms or direct therapeutic…